NCT04358133View on ClinicalTrials.gov

Low Dose Morphine to Relieve Dyspnea in Acute Respiratory Failure (OPIDYS)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Acute Respiratory Failure
Interventions
DRUG

Chlorhydrate de morphine

The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol

DRUG

NaCl 0,9%,

The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm

Trial Locations (1)

75013

Groupe Hospitalier Pitié Salpetriere, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04358133 - Low Dose Morphine to Relieve Dyspnea in Acute Respiratory Failure (OPIDYS) | Biotech Hunter | Biotech Hunter